Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM4B | O94953 | 1/20 | 0.30 |
| ▸ | KDM5C | P41229 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.30 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.30 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11985462 | 0.74 | HCAR1 (0.38) | GRIA1GRIA2GRIA3GRIA4KDM4E | |
| SCHEMBL1747901 | 0.73 | UHRF1 (0.37) | UHRF1 | |
| SCHEMBL29697758 | 0.73 | GRIA1 (0.46) | GRIA1GRIA2GRIA3GRIA4BCHE | |
| SCHEMBL30538678 | 0.73 | UHRF1 (0.37) | UHRF1 | |
| SCHEMBL858288 | 0.73 | SRC (0.34) | — | |
| SCHEMBL4929162 | 0.73 | GRIA1 (0.55) | GRIA1GRIA2GRIA3GRIA4BCHE | |
| SCHEMBL17786631 | 0.71 | KDM4A (0.35) | GRIA1GRIA2GRIA3GRIA4KDM4E | |
| SCHEMBL2255938 | 0.70 | KDM4E (0.48) | GRIA1GRIA2GRIA3GRIA4BCHE | |
| SCHEMBL6015897 | 0.69 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4BCHE | |
| SCHEMBL1374558 | 0.69 | PRKCI (0.44) | KDM4EMAPTCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| EP-1873150-A1 | Fluorinated indoleamides useful as ligands of the ORL-1 receptor | NIKEM RESEARCH S.R.L. (IT) | 2008-01-02 | — | — | EP | disclosed |
| EP-1841755-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2007-10-10 | — | — | EP | disclosed |
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | GLAXOSMITHKLINE S.P.A. (IT) | 2007-08-23 | — | — | US | disclosed |
| WO-2006070001-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676843-A1 | Substituted indole ligands for the ORL-1 receptor | NIKEM RESEARCH S.R.L. (IT) | 2006-07-05 | — | — | EP | disclosed |
| EP-1648881-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | GlaxoSmithKline S.p.A. (IT) | 2006-04-26 | — | — | EP | disclosed |
| US-20050228023-A1 | Agonist and antagonist ligands of the nociceptin receptor | SRI INTERNATIONAL (US) | 2005-10-13 | — | — | US | disclosed |
| WO-2005060947-A2 | AGONIST AND ANTAGONIST LIGANDS OF THE NOCICEPTIN RECEPTOR | SRI INTERNATIONAL (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005005411-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | GLAXOSMITHKLINE S.P.A. (IT) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005004896-A1 | NOP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PARKINSON’S DISEASE | UFPEPTIDES S.R.L. (IT) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228023-A1 | Agonist and antagonist ligands of the nociceptin receptor | OPRL1, OPRK1, OPRM1 | GRIA1 146/4885GRIA2 135/4885GRIA3 114/4885 |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | OGFRL1, OPRL1, ORMDL3 | GRIA1 30/4885GRIA2 162/4885GRIA3 142/4885 |
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | OGFRL1, OPRL1, ORMDL3 | GRIA1 56/4885GRIA2 215/4885GRIA3 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.